What is aTyr Pharma?
aTyr Pharma is dedicated to the discovery and development of groundbreaking medicines by exploring the extracellular functionality and signaling pathways of tRNA synthetases. The company has established a robust global intellectual property portfolio targeting protein compositions derived from 20 tRNA synthetase genes and their associated extracellular targets. Its primary clinical-stage product candidate, efzofitimod, is designed to modulate the neuropilin-2 receptor, aiming to downregulate immune engagement in inflammatory lung diseases. This focus positions aTyr Pharma at the forefront of biotherapeutic innovation, addressing unmet needs in complex inflammatory conditions.
How much funding has aTyr Pharma raised?
aTyr Pharma has raised a total of $340.3M across 9 funding rounds:
Series B
$10.5M
Series C
$23M
Series D
$49M
Debt
$10M
Series E
$76M
Stock Offering
$86M
Debt
$20M
Share Placement
$45.8M
Share Placement
$20M
Series B (2007): $10.5M with participation from Cardinal Partners, Alta Partners, Polaris Partners, and Imagene
Series C (2010): $23M led by Cardinal Partners, Polaris Ventures, Domain Associates, and Alta Partners
Series D (2013): $49M supported by Polaris Partners, Cardinal Partners, Domain Associates, and Alta Partners
Debt (2013): $10M featuring Silicon Valley Bank
Series E (2015): $76M backed by Cardinal Partners, EcoR1 Capital, Deerfield, Domain Associates, Polaris Partners, Sphera Global Healthcare, Rock Springs Capital Management, Federated Investors, Alta Partners, T. Rowe Price Associates, and Sofinnova Ventures
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Debt (2016): $20M led by Solar Capital and Silicon Valley Bank
Share Placement (2017): $45.8M supported by Viking Global Investors, Redmile Group, and EcoR1 Capital
Share Placement (2020): $20M featuring Aspire Capital Fund
Key Investors in aTyr Pharma
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for growth.
Cardinal Partners
Cardinal Partners is a leading venture capital partnership exclusively focused on healthcare investing, specializing in early-stage financing rounds as a lead investor.
Domain Associates
Domain Associates is an investment advisory firm established in 1985, specializing in biotech investments with a strong track record of IPOs and M&A events.
What's next for aTyr Pharma?
With substantial enterprise-level backing and a recent strategic investment, aTyr Pharma is poised for accelerated development and potential commercialization of its pipeline. The company's ongoing research into tRNA synthetase pathways and its lead candidate, efzofitimod, suggest a strategic trajectory focused on expanding its therapeutic reach within inflammatory lung diseases and potentially other indications. Future capital infusion will likely support further clinical trials, regulatory submissions, and the scaling of manufacturing capabilities, reinforcing its position in the competitive biopharmaceutical landscape.
See full aTyr Pharma company page
